Merck/Bayer set to challenge Novartis in heart failure after...

Merck & Co and Bayer’s heart failure drug vericiguat has hit its target in a phase 3 trial, vindicating a decision by the big US pharma to buy into the project for $1 billion.<

Roche increases IPF presence with $1.39bn Promedior buy

Roche has agreed to buy US biotech Promedior, and a portfolio of drugs including a promising molecule for the deadly lung-scarring disease idiopathic pulmonary fibrosis (IPF) in a deal wort

Allergan bolsters aesthetics pipeline with Exicure hair loss...

Kiadis sheds half its staff as lead cell therapy bombs

Solid Bio hit as FDA slaps clinical hold on DMD gene therapy

Boehringer, Lilly start acute heart failure trial with Jardi...